# Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

> **NCT03313206** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 60 (estimated)

## Conditions studied

- Head and Neck Mucosal Melanomas

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Surgery
- **RADIATION:** IMRT
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT03313206
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-28
- **Primary completion:** 2027-01
- **Final completion:** 2029-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03313206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03313206, "Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03313206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*